Format

Send to

Choose Destination
Cancer Treat Res. 2016;167:231-50. doi: 10.1007/978-3-319-22539-5_9.

Checkpoint Blockade for the Treatment of Advanced Melanoma.

Author information

1
Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
2
Weill Medical College of Cornell University, New York, NY, USA.
3
Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. PostowM@mskcc.org.
4
Weill Medical College of Cornell University, New York, NY, USA. PostowM@mskcc.org.

Abstract

Immunotherapy with immune checkpoint inhibition has been improving the outcomes of patients with many different types of malignancies. Immune checkpoint inhibition has been most extensively studied in patients with advanced melanoma and there are three FDA approved antibodies already widely used in clinical practice (ipilimumab, nivolumab, and pembrolizumab). In this chapter, we review the mechanistic basis behind the development of immune checkpoint blocking antibodies. We then discuss specifics regarding each agent, unique clinical considerations in treating patients with this approach, and future directions, including combination strategies. This chapter is focused on melanoma, but the principles related to this immunotherapy approach are applicable to patients with many types of malignancies.

KEYWORDS:

Immune checkpoint; Immune-related adverse events; Immune-related response criteria; Immunotherapy; Melanoma

PMID:
26601865
DOI:
10.1007/978-3-319-22539-5_9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center